FEBS Letters 2005-01-03

Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4.

Marvin T Nieman, Eileen Pagan-Ramos, Mark Warnock, Yelena Krijanovski, Ahmed A K Hasan, Alvin H Schmaier

Index: FEBS Lett. 579(1) , 25-9, (2005)

Full Text: HTML

Abstract

The angiotensin converting enzyme breakdown product of bradykinin, bradykinin 1-5 (RPPGF), inhibits thrombin-induced human or mouse platelet aggregation. RPPGF binds to the exodomain of human protease-activated receptor 1 (PAR1). Studies determined if RPPGF also binds to the exodomain of human PAR4. RPPGF binds to a peptide of the thrombin cleavage site on PAR4. Recombinant wild-type and mutated exodomain of human PAR4 was prepared. The N-terminal arginine on RPPGF binds to the P2 position or proline46 on PAR4 to block thrombin cleavage. These data indicate that RPPGF influences thrombin activity by binding to the thrombin cleavage site on both PAR4 and PAR1.


Related Compounds

Related Articles:

Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.

2004-10-01

[Clin. Pharmacol. Ther. 76(4) , 379-87, (2004)]

Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.

2001-11-01

[Thromb. Haemost. 86(5) , 1296-304, (2001)]

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

2008-05-01

[J. Thromb. Haemost. 6(5) , 837-45, (2008)]

Bradykinin metabolism in rat hind limbs.

1998-08-01

[Shock 10(2) , 146-52, (1998)]

Oral thrombostatin FM19 inhibits prostate cancer.

2010-11-01

[Thromb. Haemost. 104(5) , 1044-8, (2010)]

More Articles...